API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2021/07/06/2258065/0/en/Athenex-Provides-Update-from-FDA-Type-A-Meeting-Regarding-Oral-Paclitaxel-Plus-Encequidar-for-the-Treatment-of-Metastatic-Breast-Cancer.html
https://ir.athenex.com/news-releases/news-release-details/athenex-presents-updated-phase-3-data-survival-and-tolerability#:~:text=December%209%2C%202020-,Athenex%20Presents%20Updated%20Phase%203%20Data%20on%20Survival%20and%20Tolerability,Patients%20with%20Metastatic%20Breast%20Cancer&text=OS%20versus%20IVP.-,Oral%20paclitaxel%20demonstrated%20a%20median%20PFS%20of%208.4%20months%20vs,OS%20of%2023.3%20months%20vs.
https://www.nasdaq.com/articles/stock-alert%3A-athenex-up-13-as-fda-grants-priority-review-for-nda-of-breast-cancer-drug
https://www.globenewswire.com/news-release/2020/09/01/2086762/0/en/Athenex-Announces-FDA-Acceptance-for-Filing-of-U-S-NDA-for-Oral-Paclitaxel-and-Encequidar-in-Metastatic-Breast-Cancer-with-Priority-Review.html